Processing

Please wait...

Settings

Settings

Goto Application

1. KR1020200080554 - EBP50-CONTAINING COMPOSITION FOR TREATING DAMAGED PERIPHERAL NERVES

Office
Republic of Korea
Application Number 1020180170124
Application Date 27.12.2018
Publication Number 1020200080554
Publication Date 07.07.2020
Publication Kind A
IPC
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61P 25/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
02for peripheral neuropathies
CPC
A61K 48/005
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
005characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
A61K 38/1703
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
1703from vertebrates
A61K 48/0075
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
0075characterised by an aspect of the delivery route, e.g. oral, subcutaneous
A61P 25/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
02for peripheral neuropathies
C12N 2710/10041
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
10011Adenoviridae
10041Use of virus, viral particle or viral elements as a vector
Applicants 가톨릭관동대학교산학협력단
CATHOLIC KWANDONG UNIVERSITY INDUSTRY FOUNDATION
Inventors GYUN JEE SONG
GUPTA DEEPAK PRASAD
송견지
굽타 디퍽 프르사드
Agents 특허법인지담
Title
(EN) EBP50-CONTAINING COMPOSITION FOR TREATING DAMAGED PERIPHERAL NERVES
(KO) EBP50을 포함하는 말초신경손상 치료용 조성물
Abstract
(EN)
The present invention relates to therapeutic effects of EBP50 gene on damaged peripheral nerves. More specifically, the present invention discloses damage-treatment accelerating effects of EBP50 in the peripheral nerve system, and a novel EBP50-containing vector and composition for treating damaged peripheral nerves. The vector and the composition containing the vector according to an embodiment of the present invention enable EBP50 to be expressed specifically in Schwann cells in which EBP50 functions. EBP50 introduced into Schwann cells in such a way can accelerate the recovery of sensory functions as well as motor functions which have deteriorated due to damage to the peripheral nerves, promote re-myelination of nerve cells, and help the recovery to be more complete. COPYRIGHT KIPO 2021

(KO)
본 발명은 EBP50 유전자의 말초신경손상 치료 효과에 관한 것으로, 더욱 상세하게는 말초신경계에서 EBP50이 가지는 손상의 치료 가속화 효능과, EBP50을 포함하는 신규한 말초신경손상 치료용 벡터 및 조성물을 개시한다. 본 발명의 실시예에 따른 벡터 및 상기 벡터를 포함하는 조성물은 EBP50이 기능하는 세포인 슈반세포에 특이적으로 EBP50이 발현될 수 있도록 한다. 이렇게 슈반세포에 도입된 EBP50은 말초신경 손상에 따라 저하된 운동기능은 물론 감각기능의 회복을 가속화하고 신경세포의 재수초화를 촉진하며 상기 회복이 좀더 온전하도록 할 수 있다.

Related patent documents